VIRIDIAN THERAPEUTICS APPOINTS KRISTIAN HUMER AS CHIEF
FINANCIAL OFFICER AND CHIEF BUSINESS OFFICER
BOULDER, Colo., July 26, 2021 (GLOBE NEWSWIRE) Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company advancing new
treatments for patients suffering from serious diseases but underserved by todays therapies, today announced the appointment of Kristian Humer as its new Chief Financial Officer and Chief Business Officer.
Kristian brings extensive global finance experience as our new CFO and CBO. His appointment builds upon the tremendously talented team of executives
weve already assembled in recent months, as we advance our pipeline of investigational therapies to address serious diseases with significant unmet medical needs, commented Jonathan Violin, Ph.D., President and Chief Executive Officer of
I am excited to join the Viridian team as we position the Company to rapidly advance our pipeline, beginning with our Thyroid Eye Disease
programs targeting IGF1-R. I look forward to supporting the growth and evolution of the company as we advance our mission of creating novel medicines for patients unmet needs, said Humer.
Mr. Humer spent 20 years on Wall Street, including 14 years as a life science-focused investment banker. He brings significant experience in capital
raising, mergers and acquisitions, and partnering to Viridian. Most recently, he served as Managing Director of Banking, Capital Markets & Advisory for the Global Healthcare team at Citigroup, Inc. In this role he helped lead the
firms investment banking advisory engagements for small- and mid-sized biopharma and select large cap pharmaceutical companies. He previously served in a number of roles at Citigroup Inc. as part of
their Global Healthcare team. Prior to joining Citigroup Inc., Mr. Humer served as Vice President of the Investment Banking Division for the Global Healthcare team at Lehman Brothers, Inc.. Mr. Humer started his career serving positions of
increasing responsibility in the investment banking and private banking divisions of UBS AG and Merrill Lynch (a Bank of America company). He received an MBA from the Fuqua School of Business at Duke University, and a B.A. (Hons) in
Accounting & Economics from the University of Reading, United Kingdom.
Notice of Issuance of Inducement Grant
Pursuant to his employment agreement, Mr. Humer will be awarded an option to purchase 360,000 shares of the Companys common stock (the
Inducement Grant). The Inducement Grant will be issued outside of the Companys Amended and Restated 2016 Equity Incentive Plan (the Plan) but will remain subject to the terms and conditions of such Plan. The Inducement
Grant will be granted as an inducement material to such individuals entrance into employment with Viridian in accordance with Nasdaq Listing Rule 5635(c)(4). A majority of the independent directors serving on the Companys Board of
Directors approved Inducement Grant.
The Inducement Grant will have an exercise price equal to the closing price of Viridians common stock on
July 26, 2021, the date of grant. The Inducement Grant will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the date of grant, and thereafter the remainder of
the shares vest in 36 equal monthly installments, subject to Mr. Humers continued employment through the applicable vesting dates.